ArticleJournal of hepatocellular carcinoma2026
Construction and Validation of a Predictive Model for Post-TACE Recurrence Risk in Hepatocellular Carcinoma: A Retrospective Cohort Study.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transarterial chemoembolization (TACE) is widely used for unresectable hepatocellular carcinoma (HCC) and as adjuvant therapy to prevent postoperative recurrence. However, accurate prognostic models for HCC patients undergoing TACE remain underutilized clinically. Methods: This retrospective study included 265 HCC patients who underwent TACE, randomly assigned to training and validation sets (6:4 ratio). Recurrence-related risk factors were identified using Cox regression and further screened by Least Absolute Shrinkage and Selection Operator (LASSO) regression. A prognostic nomogram was constructed, with decision curve analysis (DCA) assessing its clinical utility. Results: Univariate Cox regression identified sex, vascular invasion, ascites, modified albumin-bilirubin grade (mALBI), China Liver Cancer (CNLC) staging, white blood cell count, neutrophils, fibrinogen (Fib), and neutrophil-to-lymphocyte ratio as significant risk factors (all HR > 1, P < 0.05). Albumin (ALB), prognostic nutritional index, and alkaline phosphatase-to-albumin ratio (AAPR) were protective factors (all HR < 1, P < 0.05). Multivariate analysis identified elevated Fib and higher CNLC stage as independent predictors (all P < 0.05). LASSO extracted vascular invasion, neutrophils, ALB, activated partial thromboplastin time, Fib, and AAPR as prognostic variables. Areas under the ROC curve at 6 months, 1 year, and 2 years were 0.717, 0.794, and 0.884, respectively. DCA demonstrated greater net clinical benefit than Barcelona Clinic Liver Cancer and CNLC staging systems. Risk stratification by nomogram tertiles showed significantly earlier recurrence in high-risk patients (all P < 0.05). Conclusion: This TACE-based prognostic nomogram integrating clinical and laboratory parameters accurately predicts postoperative recurrence and enables individualized risk stratification, assisting clinicians in tailoring interventions and delivering personalized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.